ProShares UltraShort NASDAQ Biotechnology
6 hedge funds and large institutions have $1.08M invested in ProShares UltraShort NASDAQ Biotechnology in 2024 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 1 closing their positions.
26% more capital invested
Capital invested by funds: $858K → $1.08M (+$221K)
3.42% more ownership
Funds ownership: 11.4% → 14.82% (+3.4%)
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
14% less funds holding
Funds holding: 7 → 6 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$454K |
| 2 |
Morgan Stanley
New York
|
+$32 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$255K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$163K |
| 3 |
PIS
POM Investment Strategies
Raleigh,
North Carolina
|
-$75 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $704K | +$454K | +14,088 | +268% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $275K | -$255K | -7,892 | -51% |
|
|
TRCT
3
Tower Research Capital (TRC)
New York
| $96.8K | -$163K | -5,055 | -66% |
|
4
Citigroup
New York
| $1.55K | – | – | – |
|
|
5
Morgan Stanley
New York
| $1.37K | +$32 | +1 | +3% |
|
6
UBS Group
Zurich,
Switzerland
| $18 | – | – | – |
|
|
PIS
7
POM Investment Strategies
Raleigh,
North Carolina
| – | -$75 | -3 | Closed |
|
BIS Hedge Fund Activity: Q4 2024 in Review
6 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q4 2024, worth a combined $1.08M — up 26% from $858K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of BIS and 0 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 2 added.
The largest buyer was Jane Street, adding an estimated $454K. The largest seller was Susquehanna International Group, cutting an estimated $255K.
- 6 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q4 2024, down from 7 in Q3 2024.
- Funds reported $1.08M of ProShares UltraShort NASDAQ Biotechnology stock for Q4 2024, up 26% quarter-over-quarter.
- 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q4 2024 and 1 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q4 2024 was Jane Street, an estimated $454K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q4 2024 was Susquehanna International Group, an estimated $255K sold.
Based on aggregated 13F filings for Q4 2024.